Baiyang Pharmaceutical announced that the company plans to jointly fund the establishment of the Mentougou Baiyang Phase III Pharmaceutical Industry Investment Fund with Baiyang Zhongxin, the Jingxi Industry Guidance Fund, and Gongqingcheng Wanheng. The total pledge scale of the fund is 400 million yuan. As a limited partner, the company has pledged 156 million yuan in its own capital, accounting for 39% of the total investment. The transaction constitutes a related joint investment. It has been reviewed and approved by the company's board of directors and still needs to be submitted to the shareholders' meeting for review. The fund focuses on investing in major health projects such as breakthrough technology drugs and disruptive medical devices. It is currently in the preparation stage, and there is uncertainty about implementation.

Baiyang Pharmaceutical announced that the company plans to jointly fund the establishment of the Mentougou Baiyang Phase III Pharmaceutical Industry Investment Fund with Baiyang Zhongxin, the Jingxi Industry Guidance Fund, and Gongqingcheng Wanheng. The total pledge scale of the fund is 400 million yuan. As a limited partner, the company has pledged 156 million yuan in its own capital, accounting for 39% of the total investment. The transaction constitutes a related joint investment. It has been reviewed and approved by the company's board of directors and still needs to be submitted to the shareholders' meeting for review. The fund focuses on investing in major health projects such as breakthrough technology drugs and disruptive medical devices. It is currently in the preparation stage, and there is uncertainty about implementation.